Evaluation of mexiletine effect on conduction delay and bradyarrhythmic complications in patients with myotonic dystrophy type 1 over long-term follow-up

Myotonic dystrophy type 1 (DM1) is a multisystemic disorder characterized by progressive cardiac conduction impairment, arrhythmias and sudden death. Mexiletine is a sodium-channel blocker drug used in such patients for the treatment of myotonia, even if definitive proof of its safety over long-term follow-up is lacking

Source: Heart Rhythm - June 5, 2020 Category: Cardiology Authors: Riccardo Vio, Alessandro Zorzi, Luca Bello, Virginia Bozzoni, Annalisa Botta, Francesco Rivezzi, Loira Leoni, Federico Migliore, Emanuele Bertaglia, Sabino Iliceto, Elena Pegoraro, Domenico Corrado, Chiara Calore Source Type: research